FREEHOLD, N.J. - Avalon GloboCare Corp. (NASDAQ: ALBT), a micro-cap company with a market capitalization of $6.6 million focused on precision diagnostic consumer products and cellular therapy intellectual property, has announced the grant of a patent for its CAR-T and CAR-NK cell technology by the China National Intellectual Property Administration (CNIPA). The company's stock, currently trading at $4, has shown significant volatility, achieving a 26% gain over the past six months despite recent market pressures. The patent, entitled "Artificial Immunosurveillance Chimeric Antigen Receptor and Cells Expressing the Same," was issued with a 20-year term effective April 4, 2025.
The patent, co-developed with Arbele Limited based in Hong Kong, is a significant addition to Avalon's intellectual property strategy, expanding its global footprint. It is already protected in the U.S. and other territories under the Patent Cooperation Treaty (PCT). According to InvestingPro data, the company has achieved impressive revenue growth of 106% in the last twelve months, though it continues to face profitability challenges. The technology covered by the patent aims to improve the expansion, manufacturing, survival, and efficacy of CAR-T and CAR-Natural Killer (NK) cells, with features such as a bispecific anti-CD19xCD22 CAR design and localized cytokine induction.
David Jin, M.D., Ph.D., CEO of Avalon, stated that the patent issuance not only enhances the company's intellectual property globally but also fortifies its position in cell-based immunotherapy. With this patent, Avalon underlines its commitment to advancing innovative cancer treatments.
Avalon GloboCare is engaged in marketing the KetoAir™ breathalyzer device and is exploring additional diagnostic applications for the technology. The company also manages commercial real estate holdings. This news is based on a press release statement from the company.
The grant of this patent represents Avalon's ongoing efforts to strengthen its role in the development of advanced therapies in the healthcare sector. The company's forward-looking statements in the press release highlight its anticipation of future events impacting the company and are subject to various risks and uncertainties.
Investors and interested parties are advised that forward-looking statements are based on current expectations and assumptions and may differ materially from actual future performance due to various factors, including market conditions, economic conditions, and public policy changes. InvestingPro analysis indicates the company currently shows a weak overall financial health score of 1.09, with additional challenges including short-term obligations exceeding liquid assets. For deeper insights into Avalon's financial position and 11 more exclusive ProTips, consider exploring InvestingPro. Avalon GloboCare disclaims any obligation to update forward-looking statements, which should not be relied upon beyond the date of the press release.
In other recent news, Avalon GloboCare Corp. has reported several noteworthy developments. The company announced a merger agreement with YOOV Group Holding Limited, a provider of AI automation solutions, expected to finalize in the third quarter of 2025. YOOV's unaudited financials showed a 59.1% increase in annual revenue, reporting $45.7 million in revenue and $3.4 million in net income for 2024. Additionally, Avalon finalized an agreement to exit its 40% stake in Laboratory Services MSO, LLC, redeeming its equity interest for $1.745 million. Avalon has also secured a patent in China for its CAR therapy technology, which aims to enhance CAR-T and CAR-NK cell therapies. Furthermore, Avalon executed an exchange agreement with its Chairman, Wenzhao Lu, retiring its Series A Preferred Stock and introducing Series D Preferred Stock. These actions are part of Avalon's strategic financial management and corporate restructuring efforts. Meanwhile, Fusion Fuel Green PLC appointed Luisa Ingargiola, Avalon's CFO, to its Board of Directors, where she will chair the Audit Committee.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.